AKT1 and hepatocellular carcinoma: In addition, LLGL2 can promote cell proliferation in hepatocellular carcinoma by activating phosphatidylinositol 3-kinase (PI3K)/Akt signaling and may serve as a therapeutic target in hepatocellular carcinoma [5].